2009 IoN News Archive
- Grant for research into new epilepsy treatments
- Professor Martin Rossor has been recognised by the The Alzheimer's Association
- Drug discovery collaboration on inclusion body myositis
- PDS awards Training Fellowship to Institute of Neurology researcher to understand how the brain controls Parkinson’s symptoms
- Alan Thompson to lead UCL Partners Neurological Disorders theme
- World MS Day - Wednesday 27th May - Global initiative to highlight Multiple Sclerosis
- Queen Square leads on new UK recommendations for bladder management which can dramatically improve quality of life in Multiple Sclerosis
- John Hardy most-cited Alzheimer's disease researcher in the UK
- Prestigious awards for Institute researchers
- Drug study offers hope for Alzheimer’s treatment
- Brain activity predicts our choices
- Professor George du Boulay CBE, FRCR, FRCP
- Brain awareness week: the impact of UCL research
- Parkinson's-linked mutation makes neurons vulnerable to calcium-induced death
- Second round of NIHR Senior Investigators announced
- 'Mind-Reading' Experiment Highlights How Brain Records Memories
- Anti-malaria drug does not appear to help with human prion diseases.
- UCL Partners is one of UK’s first Academic Health Science Centres
- "Opening doors for patients with MS"
- Are we as decisive as we think?
- "Magnets stop the nightmare of tinnitus, researchers say."
- Prestigious award for Professor Hugh Bostock
- Untangling the Brain
- Young UCL Investigator Award in neuroimaging techniques
- Brain disease "resistance gene" could offer insights into CJD
- Neurology: A Queen Square Textbook
- Headache: annual evidence update
- Roads closed for powerful MRI scanner delivery
- Long-term risks lower for surgical treatment of carotid stenosis
- Memorandum of collaboration signed
- Professor John Hardy joins the ranks of science greats
- Drug study offers hope for Alzheimer's treatment
- Prestigious award for Professor David Miller
- Magnets stop the nightmare of tinnitus, researchers say.
- Brain activity predicts our choices
- Jon Driver Award
- Professor Sander named recipient of the American Epilepsy Society 2009 Clinical Science Award
- Study highlights effect of brain waves on human behaviour
- New podcast describes the significance and impact of highly cited paper
- NIH Grant for research into inherited neuropathies
- How the brain knows a dog is a dog: concept acquisition in the human brain
- Prof Elizabeth Fisher elected member of the European Molecular Biology Organization (EMBO)
- Locating literacy in the brain
- Dopamine enhances expectation of pleasure in humans
- Queen Square scientists question memory theory
- IoN scientist to front Alzheimer’s Research Trust national appeal
- New doors open to the understanding of the origin of brain tumours
Published: Jul 8, 2013 2:00:00 PM
Published: Jun 13, 2013 1:18:00 PM
Published: May 15, 2013 4:45:54 PM
Published: May 13, 2013 3:05:00 PM
Brain awareness week: the impact of UCL research
22 March 2009
Launch of ground-breaking research into prion disease
Patients are being recruited to a major new research programme which aims to develop improved ways of diagnosing and treating those suffering from fatal brain diseases, such as vCJD. The £3 million study, funded by the Department of Health, is led by Professor John Collinge (head of the IoN Department of Neurodegenerative Disease) and Dr Simon Mead from the National Prion Clinic based at the National Hospital for Neurology and Neurosurgery.
The project is being officially launched next Tuesday 24th March 2009 at the NHNN. They will closely study patients at all stages of the disease to try to develop improved ways of reaching an earlier diagnosis and to understand how best to monitor patients receiving new treatments in the future. Patients who have been diagnosed with, or are at high risk of developing, prion disease can enrol on the National Prion Monitoring Cohort.
Professor John Collinge said: “As prion diseases are quite rare, come in many forms, and can be very variable in how rapidly they progress, it can be difficult to tell if a particular drug has overall benefit. For this reason, it is very important to build up a detailed picture of the progression of the different forms of the diseases and to determine how useful various types of tests are to monitor patients.
The aim is to build up a very detailed understanding of disease progression that can then be used to compare with patients receiving new drugs in the future. “Learning how to make the diagnosis much earlier is important now, but will be increasingly important when we do have effective treatments as we will want to treat patients at the earliest possible stage, ideally before irreversible damage has occurred to the brain.”